Inhaled Nitric Oxide via High-Flow Nasal Cannula in Patients with Acute Respiratory Failure Related to COVID-19.
Abhimanyu ChandelSaloni PatoliaKareem AhmadShambhu AryalA Whitney BrownDhwani SahjwaniVikramjit KhangooraOksana A ShlobinPaula C CameronAnju SinghalArthur W HoltzclawMehul DesaiSteven D NathanChristopher S KingPublished in: Clinical medicine insights. Circulatory, respiratory and pulmonary medicine (2021)
In patients with COVID-19 respiratory failure, iNO delivered via HFNC did not reduce oxygen requirements in the majority of patients or improve clinical outcomes. Given the observed association with increased length of stay, judicious selection of those likely to benefit from this therapy is warranted.
Keyphrases
- respiratory failure
- extracorporeal membrane oxygenation
- mechanical ventilation
- nitric oxide
- end stage renal disease
- ejection fraction
- coronavirus disease
- acute respiratory distress syndrome
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- prognostic factors
- intensive care unit
- cystic fibrosis
- hydrogen peroxide
- stem cells
- cell therapy
- mesenchymal stem cells
- obstructive sleep apnea